Abstract: Methods and systems are described for power state management. A critical usage window may be configured at a gateway node. A change in a power state of the gateway node may be detected, at an interface, during the critical usage window. The power state of the gateway node may be adjusted via the interface for a set duration using a backup power node.

Abstract: Methods and systems are described for power state management. A critical usage window may be configured at a gateway node. A change in a power state of the gateway node may be detected, at an interface, during the critical usage window. The power state of the gateway node may be adjusted via the interface for a set duration using a backup power node.

Abstract: Power systems, devices, and methods include a plurality of network interfaces for providing communication to, e.g., a management server, console, or user interface. One or more controllers coupled to power circuitry determine whether a preferred one of the network interfaces has connectivity, and directs communication over the preferred network interface in response to a determination that the preferred network interface does have connectivity. The controller directs communication over an alternate one of the network interfaces in response to a determination that the preferred network interface does not have connectivity.

Abstract: Power systems, devices, and methods include a plurality of network interfaces for providing communication to, e.g., a management server, console, or user interface. One or more controllers coupled to power circuitry determine whether a preferred one of the network interfaces has connectivity, and directs communication over the preferred network interface in response to a determination that the preferred network interface does have connectivity. The controller directs communication over an alternate one of the network interfaces in response to a determination that the preferred network interface does not have connectivity.

Abstract: Methods and systems are described for power state management. A critical usage window may be configured at a gateway node. A change in a power state of the gateway node may be detected, at an interface, during the critical usage window. The power state of the gateway node may be adjusted via the interface for a set duration using a backup power node.

Abstract: Methods and systems are described for power state management. A critical usage window may be configured at a gateway node. A change in a power state of the gateway node may be detected, at an interface, during the critical usage window. The power state of the gateway node may be adjusted via the interface for a set duration using a backup power node.

Abstract: The present invention provides methods for determining the likelihood and/or severity of GvHD and the likelihood of the occurrence of transplant related mortality.

Abstract: The preferred method involves the use of an embedded data field within the video stream to transport a predetermined/known source string of data which in normal operation is carried intact through the entire head-end, grooming, distribution and access portions of the provider's network. An element or multiple elements are positioned at one or more points in the network. The elements continually monitor the stream to verify that a predetermined data string is located in the embedded data field.

Abstract: Disclosed are methods and apparatus for providing redundant data forwarding or routing capabilities. In one embodiment, a network device includes a designated router and a non-designated router. The designated router generally provides layer 3 switching or routing for data received into the network device. Although the non-designated router is active, it generally does not provide forwarding capabilities until the designated router fails. The non-designated router's logical interfaces are disabled, while the designated router's logical interfaces are enabled. The non-designated router becomes the new designated router when the first designated router fails. In general terms, the routers of the network device provide redundancy with the network being aware of only a single router within network device. That is, the network is only aware of a single router. This is accomplished by having the routers share the same IP and MAC address on each logical interface.

Abstract: Disclosed are methods and apparatus for providing redundant data forwarding or routing capabilities. In one embodiment, a network device includes a designated router and a non-designated router. The designated router generally provides layer 3 switching or routing for data received into the network device. Although the non-designated router is active, it generally does not provide forwarding capabilities until the designated router fails. The non-designated router's logical interfaces are disabled, while the designated router's logical interfaces are enabled. The non-designated router becomes the new designated router when the first designated router fails. In general terms, the routers of the network device provide redundancy with the network being aware of only a single router within network device. That is, the network is only aware of a single router. This is accomplished by having the routers share the same IP and MAC address on each logical interface.

Abstract: A method for electronically resolving a discrepancy arising in a clinical data management system is provided. The discrepancy is converted, using a conversion map, from a back-end format, used to store a clinical value corresponding to the discrepancy, into a front-end format that is compatible with a front-end study definition. The discrepancy is then transferred, while in the front-end format, to a front-end site where the clinical value associated with the discrepancy was first entered. A discrepancy response is received from the front-end site. When the discrepancy response resolves the discrepancy, the discrepancy response is stored in the clinical data management system, thereby resolving the discrepancy.

Abstract: A system of controlling and managing voice and data services in a telecommunications network includes a media gateway interface coupled to a plurality of diverse voice and data media gateways operating under diverse protocols in the telecommunications network, the media gateway interface being operable to communicate service logic with the media gateways. A media gateway controller is in communications with the media gateway interface and media gateways and carries out service logic for a voice or data service according to input received from the media gateways. The system also includes a service management subsystem in communications with the media gateway controller and being operable to provision services with customers and provide service management tools for managing the services, and a service creation subsystem in communications with the service management subsystem and being operable to provide service creation tools for creating the service logic of the services.

Abstract: A method for electronically resolving a discrepancy arising in a clinical data management system is provided. The discrepancy is converted, using a conversion map, from a back-end format, used to store a clinical value corresponding to the discrepancy, into a front-end format that is compatible with a front-end study definition. The discrepancy is then transferred, while in the front-end format, to a front-end site where the clinical value associated with the discrepancy was first entered. A discrepancy response is received from the front-end site. When the discrepancy response resolves the discrepancy, the discrepancy response is stored in the clinical data management system, thereby resolving the discrepancy.

Abstract: A back-end clinical definition is designed using a back-end clinical data management system (CDMS). The back-end clinical definition is automatically converted into a Remote Data Entry (front-end) study definition. The front-end study definition is transferred to a remote computer hosting a front-end RDE product where it is used to regulate the acquisition of clinical data. During the back-end clinical definition to front-end study definition conversion process, a conversion map is created. The conversion map allows for the automated conversion of clinical data acquired using the front-end RDE product to a format that can be read by the back-end CDMS. Clinical data is retrieved from remote computers hosting a front-end RDE product in an automated manner without manual back-end clinical definition/front-end study definition conflict resolution.

Abstract: A purified DNA molecule comprises a DNA sequence of approximately 15.1 kb coding for normal or mutant RYR1 protein having a molecular weight of approximately 564,740 daltons. The DNA molecule has an endonuclease restriction map of FIG. 1 and a sequence of FIG. 2.

Abstract: A purified DNA molecule comprises a DNA sequence of approximately 15.1 kb coding for normal or mutant RYR1 protein having a molecular weight of approximately 564,740 daltons. The DNA molecule has an endonuclease restriction map of FIG. 1 and a sequence of FIG. 2.

Abstract: Compounds of formula (I): ##STR1## wherein ##STR2## is a 5-membered heterocyclic group having a 6-.pi.electron system, the five ring atoms being either(a) one carbon atom and four atoms selected from carbon and nitrogen,(b) two carbon atoms, two nitrogen atoms and one atom selected from oxygen and sulphur, or(c) four carbon atoms and one atom selected from oxygen and sulphurand R.sup.1 is a substituent on a carbon or nitrogen of ##STR3## selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl aryl, aralkyl and heterocyclyl, each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl,and, where appropriate, R.sup.2 is a substituent on a carbon or nitrogen of ##STR4## and when present is the same or different to R.sup.1 and is selected from C.sub.1-20 alkyl, C.sub.2-8 alkenyl, aryl, aralkyl and heterocyclyl each of which may optionally be substituted; hydrogen and C.sub.3-7 cycloalkyl, have antibacterial and antimycoplasmal activity.

Abstract: A compound of the formula (I) ##STR1## wherein R is a group ##STR2## R.sup.1 is hydrogen, phenyl, C.sub.1-20 alkyl, C.sub.2-8 alkenyl or C.sub.2-8 alkynyl each of which may optionally be substituted; or C.sub.3-7 cycloalkyl,X is a divalent group --Y--C.dbd.C--, andY is oxygen or sulphur,have antibacterial and/or antimycoplasmal activity.

Abstract: Compounds of formula (II): ##STR1## wherein Y is --CH.dbd.CH--CH.sub.2 --CH-- or ##STR2## R.sup.1 is hydrogen or C.sub.1-4 alkyl, R.sup.2 is hydrogen or C.sub.1-6 alkyl,R.sup.3 is hydrogen, nitro or C.sub.1-6 alkyl and, when Y represents ##STR3## and R.sup.2 and R.sup.3 are hydrogen, the nitro radical is in the meta- or para- position on the benzene ring.are novel and have antimycoplasmal activity. They may be produced by esterification of the corresponding carboxylic acid salt.